Schrödinger Expects 2024 Software Revenue Growth Of 8%-13% Versus Prior Guidance Of 6%-13%, With Drug Discovery Revenue Guidance Of $20M-$30M Compared To $30M-$35M Expected Earlier

Benzinga11-12 19:55

2024 Financial Outlook

Today Schrödinger updated its 2024 full-year financial guidance. The company's updated financial expectations for the fiscal year ending December 31, 2024, are as follows:

Software revenue growth is now expected to range from 8% to 13%.
Drug discovery revenue is now expected to range from $20 million to $30 million.
Software gross margin is expected to be slightly lower than 2023 and in the range of 2022 based on the effect of the research grant from the Bill & Melinda Gates Foundation.
Operating expense growth in 2024 is expected to range from 8% to 10%.
Cash used for operating activities in 2024 is expected to be above cash used for operating activities in 2023, depending on the timing of cash received from collaborations.

"We have increased the lower end of our software revenue growth guidance for the year, reflecting our confidence in the opportunities to meet our growth goals and the continued enthusiasm for the deployment of computation in drug discovery across the industry," stated Geoff Porges, MBBS, chief financial officer of Schrödinger. "Collaborations continue to be an important element of our business model, and we are pleased Novartis has recognized the value of our platform and the capabilities of our team with this agreement. This quarter we added $48 million to our cash balance as a result of Lilly's acquisition of Morphic and expect to add even more capital from the payments associated with the collaboration announced today."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2482708883?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-12 19:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2482708883","market":"hk","top_or_hot":-1,"title":"Schrödinger Expects 2024 Software Revenue Growth Of 8%-13% Versus Prior Guidance Of 6%-13%, With Drug Discovery Revenue Guidance Of $20M-$30M Compared To $30M-$35M Expected Earlier","media":"Benzinga","content":"<html><body><p><strong>2024 Financial Outlook</strong></p><p>Today Schrödinger updated its 2024 full-year financial guidance. The company's updated financial expectations for the fiscal year ending December 31, 2024, are as follows:</p><ul><li>Software revenue growth is now expected to range from 8% to 13%.</li><li>Drug discovery revenue is now expected to range from $20 million to $30 million.</li><li>Software gross margin is expected to be slightly lower than 2023 and in the range of 2022 based on the effect of the research grant from the Bill &amp; Melinda Gates Foundation.</li><li>Operating expense growth in 2024 is expected to range from 8% to 10%.</li><li>Cash used for operating activities in 2024 is expected to be above cash used for operating activities in 2023, depending on the timing of cash received from collaborations.</li></ul><p>\"We have increased the lower end of our software revenue growth guidance for the year, reflecting our confidence in the opportunities to meet our growth goals and the continued enthusiasm for the deployment of computation in drug discovery across the industry,\" stated Geoff Porges, MBBS, chief financial officer of Schrödinger. \"Collaborations continue to be an important element of our business model, and we are pleased Novartis has recognized the value of our platform and the capabilities of our team with this agreement. This quarter we added $48 million to our cash balance as a result of Lilly's acquisition of Morphic and expect to add even more capital from the payments associated with the collaboration announced today.\"</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Schrödinger Expects 2024 Software Revenue Growth Of 8%-13% Versus Prior Guidance Of 6%-13%, With Drug Discovery Revenue Guidance Of $20M-$30M Compared To $30M-$35M Expected Earlier</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSchrödinger Expects 2024 Software Revenue Growth Of 8%-13% Versus Prior Guidance Of 6%-13%, With Drug Discovery Revenue Guidance Of $20M-$30M Compared To $30M-$35M Expected Earlier\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-12 19:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/24/11/41896269/schr-dinger-expects-2024-software-revenue-growth-of-8-13-versus-prior-guidance-of-6-13-with-drug-><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2024 Financial OutlookToday Schrödinger updated its 2024 full-year financial guidance. The company's updated financial expectations for the fiscal year ending December 31, 2024, are as follows:...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/24/11/41896269/schr-dinger-expects-2024-software-revenue-growth-of-8-13-versus-prior-guidance-of-6-13-with-drug-\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SDGR","symbol_name":"Schrodinger Inc.","start_time":0,"source_url":"https://www.benzinga.com/general/biotech/24/11/41896269/schr-dinger-expects-2024-software-revenue-growth-of-8-13-versus-prior-guidance-of-6-13-with-drug-","article_id":"2482708883","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482708883","pubTimestamp":1731412509,"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"2024 Financial OutlookToday Schrödinger updated its 2024 full-year financial guidance. The company&#39;s updated financial expectations for the fiscal year ending December 31, 2024, are as follows:Software revenue growth is","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SDGR":"Schrodinger Inc."},"translate_title":"Schrödinger预计2024年软件收入增长8%-13%，而之前的指导为6%-13%，药物发现收入指导为2000万-3000万美元，而之前的预期为3000万-3500万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SDGR":0.9},"content_text":"2024 Financial OutlookToday Schrödinger updated its 2024 full-year financial guidance. The company's updated financial expectations for the fiscal year ending December 31, 2024, are as follows:Software revenue growth is now expected to range from 8% to 13%.Drug discovery revenue is now expected to range from $20 million to $30 million.Software gross margin is expected to be slightly lower than 2023 and in the range of 2022 based on the effect of the research grant from the Bill & Melinda Gates Foundation.Operating expense growth in 2024 is expected to range from 8% to 10%.Cash used for operating activities in 2024 is expected to be above cash used for operating activities in 2023, depending on the timing of cash received from collaborations.\"We have increased the lower end of our software revenue growth guidance for the year, reflecting our confidence in the opportunities to meet our growth goals and the continued enthusiasm for the deployment of computation in drug discovery across the industry,\" stated Geoff Porges, MBBS, chief financial officer of Schrödinger. \"Collaborations continue to be an important element of our business model, and we are pleased Novartis has recognized the value of our platform and the capabilities of our team with this agreement. This quarter we added $48 million to our cash balance as a result of Lilly's acquisition of Morphic and expect to add even more capital from the payments associated with the collaboration announced today.\"","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482708883"}